Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study [0.03%]
免疫检查点抑制剂治疗乙型肝炎表面抗原阳性肺癌患者的有效性和安全性：真实世界队列研究
Xiaohuan Zhou,Yi Feng,Jie Liang et al.
Xiaohuan Zhou et al.
Objective: This study evaluated the efficacy and hepatic safety of first-line chemoimmunotherapy in lung cancer patients according to baseline hepatitis B surface antigen (HBsAg) status, and explored whether baseline anti...
Evaluating health-related quality of life questionnaires in capturing common symptomatic adverse events in non-small cell lung cancer [0.03%]
健康相关生活质量问卷在非小细胞肺癌常见症状不良事件中的应用评价
Lotte van der Weijst,Cecilia Pompili,Maria Teixeira et al.
Lotte van der Weijst et al.
Introduction: Despite advancements in adverse events (AEs) reporting, discrepancies often arise between clinician-assessed and patient-reported symptomatic AEs, including in non-small cell lung cancer (NSCLC) trials. This...
Clinicopathological and prognostic validation of pulmonary carcinoid/NET G3: evidence for a distinct subgroup of well-differentiated neuroendocrine neoplasms [0.03%]
肺类癌/神经内分泌肿瘤G3的临床病理和预后验证：良好分化神经内分泌肿瘤的一个亚组的证据
Jules Kirmann,Marc Riffet,Céline Bazille et al.
Jules Kirmann et al.
Background: Pulmonary neuroendocrine neoplasms (NENs) comprise a biological spectrum ranging from well-differentiated carcinoid tumors to poorly differentiated neuroendocrine carcinomas. In 2026, the International Associa...
Development and validation of a risk-stratification model for individualized management of leptomeningeal metastases in EGFR- mutant NSCLC (LM-Index) [0.03%]
EGFR突变型NSCLC脑膜转移个体化管理的危险分层模型（LM-Index）的建立和验证
Yingxi Wu,Haiyang Chen,Yufeng Wu et al.
Yingxi Wu et al.
Purpose: Prognosis for patients with EGFR- mutant non-small-cell lung cancer and leptomeningeal metastasis is highly uncertain, complicating treatment decisions. We aimed to develop and validate a multimodal risk score fo...
Prediction of spread through air spaces with biopsy specimens in early-stage adenocarcinoma of the lung [0.03%]
基于早期肺腺癌病理切片的淋巴结转移和肿瘤复发风险预测研究
Tomoki Nishimura,Masanori Shimomura,Satoru Okada et al.
Tomoki Nishimura et al.
Background: We aimed to develop a preoperative risk score to predict spread through air spaces (STAS) in small-sized adenocarcinoma of the lung using clinical and biopsy-derived factors. ...
Impact of immunotherapy on overall survival and healthcare costs in advanced/metastatic lung cancer: A real-world study in France [0.03%]
免疫治疗对法国晚期/转移性肺癌患者总体生存率和医疗费用的影响：一项真实世界研究
Adrien Rousseau,Astrid Foix-Colonier,Joël Luu et al.
Adrien Rousseau et al.
Introduction: While immunotherapies have shown a substantial overall survival (OS) benefit in clinical trials, their effectiveness and costs should be assessed in real-world setting. This study aims to assess OS and healt...
Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma [0.03%]
表观蛋白质组学鉴定组蛋白H4过度乙酰化为胸膜间皮瘤预后标志物
Roberta Noberini,Ioanna Bischinioti,Simone Zanetti et al.
Roberta Noberini et al.
Pleural mesothelioma (PM) is an aggressive tumor that arises from mesothelial cells as a consequence of asbestos exposure. Despite recent therapeutic advances, the prognosis of PM remains poor, with a median overall survival typically below...
A novel MYO5C-ALK fusion in lung adenocarcinoma: limited alectinib response and durable lorlatinib benefit [0.03%]
肺癌腺癌中MYO5C-ALK融合的新发现：艾乐替尼治疗效果有限，洛拉替尼疗效持久
Tai-Yun Wu,Nien-Tzu Liu,Yu-Cheng Wu et al.
Tai-Yun Wu et al.
Objectives: Anaplastic lymphoma kinase (ALK) rearrangements drive approximately 5% of non-small cell lung cancers (NSCLC), most commonly as EML4-ALK, but rare 5' partners may confer distinct pharmacologic behaviour. We re...
CT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancer [0.03%]
不可手术的III期非小细胞肺癌根治性治疗后的CT监测、复发模式及补救治疗条件分析
C Ho,M F D&#x;amours,E Bhang et al.
C Ho et al.
Introduction: Survival rates of unresectable stage III non-small cell lung cancer (NSCLC) have improved with the introduction of durvalumab following chemoradiotherapy. Post-treatment surveillance remains crucial due to t...